| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Plasminogen , plasminogen activators ( PA ) , tissue type plasminogen activator ( t PA ) , urokinase type plasminogen activator ( u PA ) , alpha 2 antiplasmin ( alpha 2 AP ) , plasminogen activator inhibitor ( PAI ) , fibrinogen / fibrin degradation products ( FDP ) and D dimer were determined to elucidate the role of plasminogen activators and inhibitors in the pathogenesis of accelerated fibrinolysis in schistosomiasis . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| When 10 micrograms / ml u PA were added to pooled normal plasma and incubated for 30 min at an ambient temperature ( 25 degrees C ) , alpha 2 antiplasmin decreased to 8 % of the control value . ^^^ The anti u PA antibody afforded full protection of alpha 2 antiplasmin at therapeutic levels of u PA . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Role of alpha 2 antiplasmin in fibrin specific clot lysis with single chain urokinase type plasminogen activator in human plasma . ^^^ The role of plasma alpha 2 antiplasmin ( alpha 2 AP ) in the fibrin specificity of clot lysis by recombinant single chain urokinase type plasminogen activator ( rscu PA ) and in the conversion of rscu PA to its two chain derivative ( rtcu PA , urokinase ) was investigated in an in vitro human plasma clot lysis system . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| The presence and localization of the plasmin system components urokinase ( UPA ) , tissue type plasminogen activator ( TPA ) , plasminogen ( PG ) , a neoantigen expressed by the plasmin alpha 2 antiplasmin complex , and plasmin inhibitors alpha 2 antiplasmin ( AP ) and alpha 2 macroglobulin ( MG ) have been tested by immunofluorescence on sections of 11 benign and 40 malignant lesions of the breast in an attempt to apply a morphological approach to the problem of tumor invasion in vivo . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| During pregnancy , the t PA and prourokinase ( u PA ) antigen concentrations increased 50 % and 200 % , respectively , whereas the plasminogen and alpha 2 antiplasmin levels remained constant . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Monoclonal antibodies to tissue type plasminogen activator ( t PA ) , urokinase ( u PA ) and alpha 2 antiplasmin were obtained by immunizing Balb C mice with the respective purified antigens and fusion of spleen cells with mouse myeloma cells ( NSO ) . ^^^ The lower detection limit for determination of t PA was found to be 0 . 5 ng / ml , for determination of u PA 0 . 05 ng / ml , and for determination of alpha 2 antiplasmin 5 ng / ml . . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| The relative topographical distribution of urokinase type plasminogen activator ( uPA ) , tissue type PA ( tPA ) , PA inhibitor 1 ( PAI 1 ) , PA inhibitor 2 ( PAI 2 ) , plasmin ( ogen ) , alpha 2 antiplasmin , and alpha 2 macroglobulin was studied in lesional epidermis of psoriasis vulgaris , and in normal epidermis , by immunohistochemistry . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Indocyanine green concentrations , total urokinase type plasminogen activator ( u PA ) antigen , two chain u PA activity , fibrinogen , total degradation products , alpha 2 antiplasmin , and factor 12 dependent fibrinolytic activity were measured . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| In a placebo controlled , blinded crossover study , eight volunteers were challenged twice with an intravenous bolus injection of endotoxin ( 40 EU / kg of body weight ) and concurrently received either rBPI 23 ( 1 mg / kg ) or placebo ( human serum albumin , 0 . 2 mg / kg ) . rBPI 23 treatment significantly lowered the endotoxin induced fibrinolytic response , ie , reduced the release of tissue type plasminogen activator , urokinase type plasminogen activator , plasminogen activator inhibitor antigen , and complex formation of plasmin alpha 2 antiplasmin ( P = . 0078 for each ) . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Moreover , the enhanced activation of pro uPA and plasminogen observed in the presence of cells was significantly less susceptible to inhibition by alpha 2 antiplasmin . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Venous blood samples were taken at time 0 , 3 , 6 , 25 and 49 h for assay of fibrinogen ( Fbg ) , fibrinopeptide A ( FPA ) , total fibrin ( ogen ) degradation products ( TDP ) , fibrin degradation products ( FbDP ) , fibrinogen degradation products ( FgDP ) , cross linked fibrin degradation products ( XL FDP ) , tissue plasminogen activator ( tPA ) , urinary type plasminogen activator ( u PA ) , plasminogen , alpha 2 antiplasmin ( alpha 2 AP ) and plasminogen activator inhibitor 1 ( PAI 1 ) . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Blood samples were obtained on days 1 , 4 , and 7 after hospital admission to measure tissue type plasminogen activator antigen ( t PA ) , urokinase type plasminogen activator ( u PA ) , plasminogen activator inhibitor antigen ( PAI 1 ) , plasminogen , alpha 2 antiplasmin , fibrinogen , antithrombin 3 , protein C , protein S , thrombin antithrombin complexes ( TAT ) , D dimer , and von Willebrand factor related antigen ( vWF : Ag ) . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Lysis of blood clots from vehicle and retinoic acid treated rats could be completely blocked by addition of tranexamic acid or antibodies against rat t PA before clot formation . t PA activity in plasma was slightly increased after retinoic acid treatment ; no effects were measured on plasma PAI 1 , u PA , plasminogen , and alpha 2 antiplasmin levels . t PA activity in lung and kidney was marginally enhanced by retinoic acid but in heart and aortic tissue extracts t PA activity was increased by about 50 % . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Plasminogen activity and antigen , euglobulin fibrinolytic activity , tissue type plasminogen activator activity and antigen urokinase type plasminogen activator antigen , plasminogen activator inhibitor 1 activity and antigen , plasminogen activator inhibitor 2 antigen , tissue type plasminogen activator / plasminogen activator inhibitor complexes , alpha 2 antiplasmin , histidine rich glycoprotein , and fibrinogen / fibrin degradation products were measured in blood samples taken from the umbilical vein of 100 healthy full term newborns . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Plasma samples for prothrombin fragment 1+2 , thrombin antithrombin 3 complex , plasmin alpha 2 antiplasmin complex , tissue type plasminogen activator antigen , urokinase type plasminogen activator antigen , u PA activity , plasminogen activity , alpha 2 antiplasmin and alpha 2 macroglobulin assays were obtained from AVF and contralateral large veins of ESRD patients and from peripheral veins of the control group . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Increments in fibrinolytic parameters including tissue plasminogen activator antigen , urokinase type plasminogen activator antigen and activity , and plasminogen activity together with lower alpha 2 antiplasmin levels favor activation of fibrinolysis , except for higher alpha 2 macroglobulin concentrations , in arteriovenous fistula . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| We examined the interference of endogenous inhibitors such as plasminogen activator inhibitor 1 ( PAI 1 ) and alpha 2 antiplasmin , and that of an endogenous activator namely single chain urokinase type plasminogen activator ( scu PA ) on the Coaset t PA assay . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Plasma concentrations of indocyanine green , tissue type plasminogen activator ( t PA ) antigen , t PA activity , total u PA antigen , plasmin activatable single chain u PA ( scu PA ) , active two chain u PA ( tcu PA ) , fibrinogen , total fibrin , and fibrinogen / fibrin degradation products ( TDP ) , and alpha 2 antiplasmin were measured . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Several mechanisms contribute to this stimulation , eg , enhanced plasminogen activation by t PA or u PA , enhanced conversion of scu PA to tcu PA , and impaired inhibition of plasmin by alpha 2 antiplasmin or of PAs by PAIs . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| The function of uPA at this stage was tested using the protease inhibitors aprotinin , alpha 2 antiplasmin , or plasminogen activator inhibitor 1 ( PAI 1 ) . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Blood samples were taken at regular time intervals to measure plasma levels of urokinase type plasminogen activator ( u PA ) antigen and activity , the two chain form ( tcu PA ) activity , indocyanine green , fibrinogen , fibrin and fibrin degradation products , alpha 2 antiplasmin and thrombin antithrombin 3 complex . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| The expression of uPA , activators of uPA ( cathepsin D , antithrombin 3 ) , uPA substrates ( plasminogen , matrix metalloproteinase 2 [ collagenase 4 , 72 kD ; MMP 2 ] ) , uPA / plasmin inhibitors ( plasminogen activator inhibitor type 1 and 2 [ PAI 1 , PAI 2 ] , alpha 1 antitrypsin , alpha 2 antiplasmin ) , uPA receptor ( uPA R ) , and parameters of the uPA R cycle ( alpha 2 macroglobulin , alpha 1 antichymotrypsin ) could be determined immunohistochemically and were scored semiquantitatively in 203 patients . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Therefore , in a consecutive prospective series of 203 gastric cancer patients , the expression of activators ( plasminogen , tPA , MMP 2 , cathepsin D , antithrombin 3 ) and inhibitors ( alpha 2 antiplasmin , alpha 2 macroglobulin , alpha 1 antitrypsin , alpha 1 antichymotrypsin ) of proteolysis was studied immunohistochemically in the tumor epithelium semiquantitatively ( score 0 3 ) in addition to the uPA system . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| They amplified plasminogen activation in culture supernatants up to 70 fold by stimulating ( 1 ) pro uPA activation by plasmin and ( 2 ) plasminogen activation by uPA . ( 3 ) In addition , sulfated polysaccharides partially protected plasmin from inactivation by alpha 2 antiplasmin . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| METHODS : We studied seven variables of the coagulation pathway ( PT , aPTT , fibrinogen , FVIII : c , von Willebrand factor , thrombin antithrombin complexes , prothrombin fragments 1+2 ) and seven parameters of the fibrinolytic system ( plasminogen , alpha 2 antiplasmin , C 1 esterase inhibitor , tissue type plasminogen activator , urokinase type plasminogen activator , plasminogen activator inhibitor type 1 , D dimer ) in 24 pediatric patients with diarrhea associated hemolytic uremic syndrome and in 15 children with acute renal failure not due to hemolytic uremic syndrome . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Addition of plasminogen promoted uPA activity in both normal and OA osteoblasts via a positive feedback loop due to plasmin generation , since this activity was inhibited by both PAI 1 and alpha 2 antiplasmin . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Fibrinopeptide A ( FP A ) , D Dimer , plasminogen activators ( PA ) of the urokinase ( u PA ) or tissue type ( t PA ) , PA inhibitor 1 ( PAI 1 ) and alpha 2 antiplasmin ( alpha 2 AP ) were determined by ELISA technique . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| As the proteases of the plasminogen activator system have been implicated in tissue remodelling , cell migration and tumour invasion , we performed an immunohistochemical study to look for evidence of alteration in the expression of plasminogen / plasmin , urokinase type plasminogen activator , tissue type plasminogen activator and alpha 2 antiplasmin in biopsies of clinically typical vulval lichen sclerosus obtained from 11 untreated adult women . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| The following fibrinolysis system parameters were determined in the sera of all patients : tissue plasminogen activator concentration ( t PA : Ag ) , urokinase plasminogen activator concentration ( u PA : Ag ) , plasminogen activator inhibitor concentration ( PAI Ag ) , plasminogen level , alpha 2 antiplasmin activity ( alpha 2 AP ) , plasmin alpha 2 antiplasmin complexes concentration ( PAP ) . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Besides degrading of matrix proteins , PMN E has been shown to be able to cleave and inactivate plasminogen activator inhibitor 1 ( PAI 1 ) , the main inhibitor of uPA , and alpha 2 antiplasmin , the natural inhibitor of plasmin , thus enabling an uncontrolled matrix degradation by the fibrinolytic enzymes . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| In contrast , renal expression of several genes that regulate plasmin activity were similar in both genotypes , including uPA , tPA , PAI 1 , protease nexin 1 , and alpha 2 antiplasmin . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Plasmin , tissue plasminogen activator ( tPA ) , and urokinase plasminogen activator ( uPA ) activity , plasminogen activator inhibitor 1 ( PAI 1 ) , and alpha 2 antiplasmin ( alpha2AP ) antigen were measured in the AAA wall and juxtamural and luminal aspects of intraluminal thrombus in 18 patients . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| The latter was associated with elevated FXII and PKK , while C 1 INH was decreased , ATIII and alpha 2M were unchanged ; it could not be accounted for by changes in t PA , u PA , PAI , plasminogen , alpha 2 AP , proteins C or S . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| The balance of proteases and inhibitors differed dramatically from that observed in plasma , with higher levels of t PA , PAI 1 and PAI 2 , and lower levels of u PA ( urokinase ) , plasminogen , alpha 2 AP and t PA PAI 1 complex in bone marrow , and resulted in favourable conditions for fibrinolysis . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| METHODS : Tissue type plasminogen activator deficient ( tPA ( / ) ) , urokinase type plasminogen activator deficient ( uPA ( / ) ) , plasminogen activator inhibitor 1 deficient ( PAI 1 ( / ) ) , alpha 2 antiplasmin deficient ( alpha 2 AP ( / ) ) mice , and their wild type counterparts were used . ^^^ No significant difference was observed between uPA ( / ) or alpha 2 AP ( / ) and their wild type mice . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| RA synovium ( compared with that of patients with OA or joint trauma ) had increased numbers of macrophages and increased expression / content of fibrinogen , tissue factor , factor 13 , tissue transglutaminase , cross linked fibrin ( fibrin D dimer ) , urokinase type plasminogen activator , and alpha 2 plasmin inhibitor . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| These findings confirmed that the tissue extracts of PMM contained t PA , and that those of AP contained both t PA and urokinase type plasminogen activator ( u PA ) . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| The sequenced 5 ' flanking region ( 1 . 32 kb ) lacks a typical TATA box , but contains a CAAT box and putative binding sites for several transcription factors , such as ATF , NF IL 6 , Sp 1 , and AP 2 . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Glutathione depletion inhibits oxidant induced activation of nuclear factor kappa B , AP 1 , and c Jun / ATF 2 in cultured guinea pig gastric epithelial cells . ^^^ Gel mobility shift assay demonstrated that H2O2 and diamide rapidly activated nuclear factor kappa B ( NF kappaB ) , and diamide activated activator protein ( AP ) 1 , and c Jun / activating transcription factor ( ATF ) 2 , suggesting that the response may be coupled to these reduction oxidation ( redox ) sensitive transcription factors , as well as heat shock transcription factor 1 . ^^^ The activations of NF kappaB , AP 1 , and c Jun / ATF 2 by the oxidants did not occur in glutathione depleted cells . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| The putative promoter region of the Apex gene lacks the typical TATA box , but contains CAAT boxes and a CpG island having putative binding sites for several transcription factors , such as Sp 1 , AP 2 , GATA 1 and ATF . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| In contrast , thrombi in wt mice , t PA ( / ) and u PA ( / ) mice were comparable , substantiating efficient inhibition of fibrinolysis by the combined PAI 1 / alpha ( 2 ) AP action . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| During syncytium formation increasing protein expression of activating transcription factor ( ATF ) 1 , cAMP response element binding protein ( CREB ) 1 , and AP 2alpha was observed on Western blots . ^^^ By fluorescence immunohistochemistry , we show that CREB 1 was predominantly expressed in syncytiotrophoblasts , whereas ATF 1 and AP 2alpha localized to the syncytium and some cytototrophoblasts as well as to stromal and endothelial cells of the placental villus . ^^^ We conclude that differentiation dependent transcription of the CGalpha gene in villous trophoblasts is mainly governed by increasing expression of AP 2alpha and PKA dependent phosphorylation of CREB 1 and ATF 1 . . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| We have investigated the role of substrate binding energy in catalysis by systematically dismantling the optimal substrate Ap ( +1 ) UpA ( 1 ) pA ( 2 ) by replacing the nucleotides at the +1 , 1 , or 2 position with a tetrahydrofuran abasic site nucleotide ( D ) , a 3 hydroxypropyl phosphodiester spacer ( S ) , a phosphate monoester ( p ) , or a hydroxyl group ( h ) . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Finally , we demonstrate that constitutive secretion of uPA is repressed by Bis 1 , implying an important role for AP 1 and NF kappaB in cell migration . ^^^ Our data demonstrate a connection among PKC , constitutively active AP 1 and NF kappaB , constitutive secretion of uPA , and cell migration of highly invasive breast cancer cells . ^^^ Thus , PKC controls cell motility by regulating expression of uPA through the activation of AP 1 and NF kappaB . ^^^ The disruption of PKC , AP 1 , and NF kappaB signaling in breast cancer may be used to develop therapies for breast cancer prevention and intervention by reducing the secretion of uPA . . ^^^ Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase type plasminogen activator through activation of AP 1 and NF kappaB . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| This study gives the first clinical evidence that urokinase type plasminogen activator receptor ( u PAR ) gene expression is tumor specifically regulated via an activator protein ( AP ) 2 / Sp1 promoter element in a large patient subpopulation . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| In a previous report , we showed a progressive increase in the levels of various activator protein ( AP ) 1 components , including phosphorylated ATF 2 , in a series of mouse skin cell lines that represented developmental stages of the mouse skin carcinogenesis system . ^^^ Subsequently , we observed that dominant negative ATF 2 affected the composition and reduced the activity of AP 1 . ^^^ We attributed this behavior to the significant down regulation of cyclin D 1 , cyclin A , and ATF 3 , known AP 1 targets implicated in cell cycle control and promotion . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| Comparison of the exon intron structure of the PLI 1 gene with those of genes encoding urokinase type plasminogen activator receptor ( uPAR ) , Ly 6 , CD 59 and neurotoxins showed that they have characteristic unit encoding approximately 90 amino acid residues , which is divided over two exons . ^^^ |
|
| Interacting proteins: P08697 and P00749 |
Pubmed |
SVM Score :0.0 |
| The PA concentration required to induce 25 % [ ED 25 ] of the maximally inducible Pli activity in plasma ( = 1 U / mL = 45 mg / L = 0 . 53 micromol / L active Pli ; deltaA = 363 + / 8 mA / h RT ) after 10 minutes ( 37 degrees C ) were 320 IU / mL u PA , 8 microg / mL t PA , 140 U / mL PSAC , 6 , 000 IU / mL SK , 720 U / mL RP , and approximately 150 microg / mL TP . ^^^ |
|